Novavax, Inc. (NVAX) Presents at Goldman Sachs 46th Annual Global Healthcare Conference Transcript

Novavax, Inc. (NASDAQ:NVAX) Goldman Sachs 46th Annual Global Healthcare Conference June 11, 2025 2:00 PM ET

Company Participants

James Patrick Kelly – Executive VP, CFO & Treasurer
John Charles Jacobs – President, CEO & Director
Ruxandra Draghia-Akli – EVP and Head of Research & Development

John Charles Jacobs

Are we ready to go? Are we live? Hello, everyone. Hi, I’m John Jacobs, CEO of Novavax, and I’m joined here today by Jim Kelly, our CFO; and Dr. Ruxandra Draghia, who heads up our R&D. I want to thank everyone who’s here today to join us and listening into our presentation at the Goldman Sachs 46th Annual Global Healthcare Conference.

Today is June 11, 2025. I’ll advance the slide to our cautionary note regarding forward-looking statements. If I took the time to read all of this, we would use our full-time allotment. So I’d ask that you please review this statement and all of our risk factors in our SEC filings as well as on our corporate website before making any decisions about investment in our company.

And I’ll move on to an opening slide. And we have this slide here for those of you who are more new to the Novavax story in the last few years. We’ve evolved our business model from one that was a vertically integrated commercial company to a model that focuses more on R&D and diversified partnerships.

On the top right of the slide, you can see from 2020 to 2022, the company was a vertically integrated commercial organization with a singular focus on its first product launch, a COVID-19 vaccine called Nuvaxovid and the vast majority of company resources, expense, personnel, effort and energy were spent, bringing that vaccine forward and introducing it to the world.

In early ’23, I had the good fortune to have